Labs report sub-1% CRISPR error rates

Social posts on July 9 highlighted claims that some laboratories are reporting CRISPR error rates below 1%, a level presented online as evidence of improving precision in gene-editing workflows. The posts pointed to Cellecta workflow tools and to listed biotech companies including CRISPR Therapeutics and Intellia Therapeutics as public-market names tied to gene-editing programs. The underlying claims circulated on X rather than in a single peer-reviewed paper or company filing reviewed for this article. Company websites, however, show an expanding set of CRISPR workflow products and clinical programs that help explain why the discussion gained traction. ### Where did the sub-1% claim come from? An X post by @theCryptoBoy007 on July 9 said multiple labs were reporting CRISPR error rates under 1% and linked that to newer workflow tools and improved editing precision. The post also mentioned Cellecta and cited CRISPR Therapeutics and Intellia as companies with relevant clinical exposure, according to the social briefing provided for this story. No single lab dataset or journal article tied to that July 9 post was identified in the source material reviewed here. That means the sub-1% figure should be treated as a social-media claim unless readers can trace it to named laboratories, methods and measured error definitions in published data. ### What does Cellecta actually sell into CRISPR workflows? Cellecta says on its website that it offers genomic products and services spanning functional screens, lentiviral constructs and libraries, cell engineering, transcriptome profiling and related tools. Its CRISPR pages list knockout pooled lentiviral sgRNA libraries, sgRNA constructs and vectors, CRISPRa and CRISPRi libraries, Cas9 activity test kits and next-generation sequencing analysis for CRISPR, RNAi and barcode libraries. Those products are workflow infrastructure rather than approved medicines. Cellecta’s materials describe them as tools for target identification, validation, biomarker discovery and pooled screening, which is consistent with the way social posts framed the company’s role in the discussion. ### Why were CRSP and NTLA mentioned alongside lab tool vendors? CRISPR Therapeutics says on its website that CASGEVY, or exagamglogene autotemcel, is the first approved CRISPR-based therapy and is approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. (cellecta.com) The company says it has one approved therapy, five clinical programs and 10 preclinical programs. Intellia Therapeutics says it is developing CRISPR-based therapies and that its pipeline includes both in vivo and ex vivo programs. Its pipeline page lists lonvoguran ziclumeran, formerly NTLA-2002, and nexiguran ziclumeran, formerly NTLA-2001, among named programs. The social posts appear to have grouped those companies with the lab claims because both are established public names in gene editing, not because either company publicly reported a new sub-1% error-rate milestone on July 9 in the materials reviewed here. (crisprtx.com) ### Does a sub-1% error rate mean the same thing in every CRISPR experiment? CRISPR error-rate language can refer to different measurements, including off-target edits, unintended on-target changes, sequencing artifacts or workflow failure rates. (intelliatx.com) A percentage cited without a named assay, cell type, editor system and detection method is difficult to compare across labs. Nature reviews and other scientific literature have described rapid progress in CRISPR tools, including base editing, prime editing and AI-assisted design, but they also note that precision depends on the editing system and how off-target effects are measured. ### What should readers watch next? July 2026 social discussion is likely to move next to source documents: lab preprints, conference posters, product notes or company technical materials that define the reported error metric. Cellecta’s product pages and brochures remain the clearest public reference for the workflow tools cited online, while CRISPR Therapeutics and Intellia continue to update their pipeline pages with program milestones. (nature.com) (cellecta.com)